MedPath

Ondansetron

These highlights do not include all the information needed to use ONDANSETRON TABLETS and ONDANSETRON ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ONDANSETRON TABLETS and ONDANSETRON ORALLY DISINTEGRATING TABLETS. Initial U.S. Approval: 1991

Approved
Approval ID

c0d827d0-333f-4187-ac75-9dc7d34b6169

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 20, 2025

Manufacturers
FDA

REMEDYREPACK INC.

DUNS: 829572556

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ondansetron

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70518-3512
Application NumberANDA078152
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ondansetron
Product Specifications
Route of AdministrationORAL
Effective DateAugust 20, 2025
FDA Product Classification

INGREDIENTS (7)

ASPARTAMEInactive
Code: Z0H242BBR1
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
CROSPOVIDONE (120 .MU.M)Inactive
Code: 68401960MK
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
ONDANSETRONActive
Quantity: 4 mg in 1 1
Code: 4AF302ESOS
Classification: ACTIB
SODIUM STEARYL FUMARATEInactive
Code: 7CV7WJK4UI
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 9/7/2022

PRINCIPAL DISPLAY PANEL

DRUG: Ondansetron

GENERIC: Ondansetron

DOSAGE: TABLET, ORALLY DISINTEGRATING

ADMINSTRATION: ORAL

NDC: 70518-3512-0

NDC: 70518-3512-1

NDC: 70518-3512-2

NDC: 70518-3512-3

NDC: 70518-3512-4

NDC: 70518-3512-5

NDC: 70518-3512-6

NDC: 70518-3512-7

NDC: 70518-3512-8

COLOR: white

FLAVOR: STRAWBERRY

SHAPE: ROUND

SCORE: No score

SIZE: 7 mm

IMPRINT: G;4

PACKAGING: 30 in 1 BOX, UNIT-DOSE

PACKAGING: 6 in 1 BOX, UNIT-DOSE

PACKAGING: 10 in 1 BOX, UNIT-DOSE

PACKAGING: 20 in 1 BOX, UNIT-DOSE

PACKAGING: 12 in 1 BOX, UNIT DOSE
PACKAGING: 9 in 1 BOX, UNIT DOSE

PACKAGING: 21 in 1 BOX, UNIT DOSE

PACKAGING: 15 in 1 BOX, UNIT DOSE

PACKAGING: 3 in 1 BOX, UNIT DOSE

ACTIVE INGREDIENT(S):

  • ONDANSETRON 4mg in 1

INACTIVE INGREDIENT(S):

  • ASPARTAME
  • SILICON DIOXIDE
  • CROSPOVIDONE (120 .MU.M)
  • MAGNESIUM STEARATE
  • MANNITOL
  • SODIUM STEARYL FUMARATE

MM1

MM2

MM6

MM8

MM9

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 9/7/2022

6. Adverse Reactions

RECENT MAJOR CHANGES SECTION

LOINC: 43683-2Updated: 12/12/2024

DESCRIPTION SECTION

LOINC: 34089-3Updated: 9/7/2022

11 DESCRIPTION

The active ingredient in Ondansetron Tablets, USP is ondansetron hydrochloride, USP as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate. It has the following structural formula:

structure-hcl

The empirical formula is C 18H 19N 3O•HCl•2H 2O, representing a molecular weight of 365.85 g/mol.

Ondansetron hydrochloride, USP (dihydrate) is a white to off-white powder that is sparingly soluble in water and in alcohol; soluble in methanol, slightly soluble in isopropyl alcohol, and in dichloromethane; very slightly soluble in acetone, in chloroform and in ethyl acetate.

The active ingredient in Ondansetron Orally Disintegrating Tablets, USP is ondansetron base, the racemic form of ondansetron, and a selective blocking agent of the serotonin 5-HT 3 receptor type. Chemically it is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one. It has the following structural formula:

structure-base

The empirical formula is C 18H 19N 3O representing a molecular weight of 293.4 g/mol.

Each 4-mg Ondansetron Tablet, USP for oral administration contains ondansetron hydrochloride, USP (dihydrate) equivalent to 4 mg of ondansetron. Each 8-mg Ondansetron Tablet, USP for oral administration contains ondansetron hydrochloride, USP (dihydrate) equivalent to 8 mg of ondansetron. Each tablet also contains the inactive ingredients colloidal silicon dioxide, hypromellose, iron oxide yellow (8 mg tablet only), lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, titanium dioxide and triacetin.

Each 4-mg Ondansetron Orally Disintegrating Tablet, USP for oral administration contains 4 mg ondansetron base. Each 8-mg Ondansetron Orally Disintegrating Tablet, USP for oral administration contains 8 mg ondansetron base. Each Ondansetron Orally Disintegrating Tablet, USP also contains the inactive ingredients aspartame, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, sodium stearyl fumarate and strawberry flavor. Ondansetron Orally Disintegrating Tablets, USP are an orally administered formulation of ondansetron which rapidly disintegrates on the tongue and does not require water to aid dissolution or swallowing. This product disintegrates in approximately 60 seconds.

Ondansetron Orally Disintegrating Tablets, USP meet USP Disintegration Test 2.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 9/7/2022

16 HOW SUPPLIED/STORAGE AND HANDLING

Ondansetron Orally Disintegrating Tablets, USP

4 mg (as 4 mg ondansetron base) are white, circular, flat faced, uncoated tablets with ‘G’ engraved on one side and ‘4’ on the other side in:

NDC: 70518-3512-00

NDC: 70518-3512-01

NDC: 70518-3512-02

NDC: 70518-3512-03

NDC: 70518-3512-04
NDC: 70518-3512-05

NDC: 70518-3512-06

NDC: 70518-3512-07

NDC: 70518-3512-08

PACKAGING: 30 in 1 BOX, UNIT DOSE

PACKAGING: 6 in 1 BOX, UNIT DOSE

PACKAGING: 10 in 1 BOX, UNIT DOSE

PACKAGING: 20 in 1 BOX, UNIT DOSE

PACKAGING: 12 in 1 BOX, UNIT DOSE
PACKAGING: 9 in 1 BOX, UNIT DOSE

PACKAGING: 21 in 1 BOX, UNIT DOSE

PACKAGING: 15 in 1 BOX, UNIT DOSE

PACKAGING: 3 in 1 BOX, UNIT DOSE

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

Repackaged and Distributed By:

Remedy Repack, Inc.

625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ondansetron - FDA Drug Approval Details